Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 501

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 501
---
3    
 Class A 
 ​       
 ​       | ​ 
 ​ |          ​ 
          ​ | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Class B 
 ​       
 ​       | ​ 
 ​ |          ​ 
          ​ | ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ |
|:----------------------------------------------------|:--|:--|:----------------------------------------|:--|-----------:|:--|:--|:--|:--------|:--|-----------:|:--|:--|:--|:--------|:--|-----------:|:--|:--|:--|:--------|:--|-----------:|:--|:--|
| Net loss                                            | ​ | ​ | ​                                       | $ |     -1,625 | ​ | ​ | ​ | ​       | $ |     -1,692 | ​ | ​ | ​ | ​       | $ |     -2,064 | ​ | ​ | ​ | ​       | $ |     -2,149 | ​ | ​ |
| Denominator                                         | ​ | ​ | ​                                       | ​ |          ​ | ​ | ​ | ​ | ​       | ​ |          ​ | ​ | ​ | ​ | ​       | ​ |          ​ | ​ | ​ | ​ | ​       | ​ |          ​ | ​ | ​ |
| Basic and diluted weighted average unitsoutstanding | ​ | ​ | ​                                       | ​ | 95,555,554 | ​ | ​ | ​ | ​       | ​ | 16,666,666 | ​ | ​ | ​ | ​       | ​ | 82,546,600 | ​ | ​ | ​ | ​       | ​ | 16,666,666 | ​ | ​ |
| Basic and diluted net loss per member unit          | ​ | ​ | ​                                       | $ |      -0.02 | ​ | ​ | ​ | ​       | $ |      -0.10 | ​ | ​ | ​ | ​       | $ |      -0.03 | ​ | ​ | ​ | ​       | $ |      -0.13 | ​ | ​ |

Recently Issued Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The standard requires entities to disclose additional categories about federal, state and foreign income